CarolJFabianMD

Clinical Trials

• LY353381 in Preventing Breast Cancer in Women With Hyperplasia Start of enrollment: 2000 Aug 01

  Completed

  Phase 2

• Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer Start of enrollment: 2000 Jul 01

  Completed

  Phase 1

• Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women Start of enrollment: 2003 Jan 01

  Completed

  Phase 2

• Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer Start of enrollment: 2005 Oct 01

  Completed

• Protocol for Women at Increased Risk of Developing Breast Cancer Start of enrollment: 1989 Aug 01

  Recruiting

• An Examination of Predictors of Indicators of Response to Letrozole 2.5 mg Start of enrollment: 2003 Jan 01

  Completed

• An Examination of Predictors of Indicators of Response to Celecoxib in Women Who Have a Diagnosis of Early Breast Cancer Start of enrollment: 2003 Jan 01

  Completed

• Protocol for Women at Increased Risk of Developing Breast Cancer Start of enrollment: 2003 Jan 01

  Completed

  Phase 2

• Protocol for Women at Increased Risk of Developing Breast Cancer Start of enrollment: 2003 Apr 01

  Completed

  Phase 2

• Protocol to Examine Methylation of Tumor Suppression Genes in Women at High Risk of Developing Breast Cancer Start of enrollment: 2005 Jun 01

  Completed

• A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy Start of enrollment: 2003 Jun 01

  Completed

  Phase 1

• Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer Start of enrollment: 2005 May 01

  Withdrawn

• Study of Breast Cancer Prevention by Letrozole in High Risk Women Start of enrollment: 2006 Oct 01

  Completed

  Phase 2

• Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy Start of enrollment: 2009 Mar 01

  Terminated

  Phase 2

• Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer Start of enrollment: 2009 Feb 01

  Completed

  Phase 2

• Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. Start of enrollment: 2009 May 01

  Completed

  Phase 2

• Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression Start of enrollment: 2009 Jul 01

  Completed

  Phase 2

• A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer Start of enrollment: 2010 Jul 01

  Withdrawn

  Phase 2

• Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D Start of enrollment: 2009 May 01

  Completed

  Not Applicable

• Breast Cancer Risk Biomarkers in Premenopausal Women Start of enrollment: 2010 Nov 01

  Completed

  Phase 2

• Breast Cancer Risk Biomarkers in Postmenopausal Women Start of enrollment: 2010 Nov 01

  Completed

  Phase 2

• Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer Start of enrollment: 2011 Jan 01

  Terminated

  Phase 2

• Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer Start of enrollment: 2011 Feb 01

  Unknown status

  Phase 2

• Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women Start of enrollment: 2014 Mar 01

  Completed

  Not Applicable

• Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens Start of enrollment: 2021 Dec 14

  Recruiting

  Phase 2

  Roles: Principal Investigator, Contact

• Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer Start of enrollment: 2024 Oct 08

  Not yet recruiting

  Phase 2

  Roles: Contact, Principal Investigator

• Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial Start of enrollment: 2024 Nov 26

  Not yet recruiting

  Phase 2

  Roles: Principal Investigator, Contact

• Join now to see all